© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Colonoscopy Bowel Prep Guidelines Updated by US Multi-Society Task Force on Colorectal Cancer
March 05, 2025
New evidence-based guidance for bowel prep considers patient preference and history and updates timing of prep regimen, dietary restrictions, and follow-up recommendations.
Investigational Ketogenic Diet Pill BL-001 Shows Significant Weight Loss in Phase 1 Trial
March 05, 2025
Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.
Obesity Will Affect One-Half of Adults, One-Third of Youth Worldwide by 2050
March 04, 2025
Posing an unparalleled threat of premature disease and death globally, the unchecked rise in overweight and obesity requires an urgent 5-year action plan, experts say.
FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025
March 04, 2025
Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.
COVID-19 2024-2025 Vaccines 33% Effective Against Hospitalization, ED Visits in Adults: Early Data
March 04, 2025
CDC midseason data suggest low COVID-19 vaccine efficacy in adults aged 18 to 64 years, with somewhat better impact on those aged 65 years and older.
What to Know Before AAD 2025: Product Snapshots of Nonsteroidal Topical Treatments for Eczema
March 04, 2025
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
WHO Recommends Flu Vaccine Composition for 2025-26 Northern Hemisphere Season as US HHS Cancels ACIP, VRBAC Meetings
March 03, 2025
Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
March 03, 2025
The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.
Omalizumab Efficacy and Safety Shown Superior to OIT in First Head-to-Head Multi-Food Allergy Trial
March 03, 2025
Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
March 03, 2025
The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.